Posoleucel
Trade name: viralym-a
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02313857)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- unidentified adenovirusImmunity, passive
unidentified adenovirus immunity, passive
- BK polyomavirusImmunity, passive
BK polyomavirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- viralym-a
- viralym-b
- viralym-c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02276820 | Phase 1 | Jun 1, 2017 | Baylor University, Methodist Cancer Center, Houston, Texas, ViraCyte |
| NCT02313844 | Phase 1 | Jan 1, 2017 | Baylor University, Methodist Cancer Center, Houston, Texas, ViraCyte |
| NCT02313857 | Phase 1 | Sep 1, 2015 | Baylor University, Methodist Cancer Center, Houston, Texas, ViraCyte |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 3 | 0 | 1 | 2015 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 3 | 0 | 1 | 2015 |
| ViraCyte | For profit | 3 | 3 | 1 | 2015 |
3 organizations
Page 1 / 1